Warfarin Interactions with Antimicrobial Agents: Part I

Special feature

By Gregory Aung, PharmD Candidate: Crystal Leung, PharmD Candidate; Laura Kawamoto, PharmD Candidate, PharmD Candidates for the University of the Pacific; and Jessica C. Song, MA, PharmD, Assistant Professor, Pharmacy Practice, University of the Pacific, Stockton, CA, Pharmacy Clerkship and Coordinator, Santa Clara Valley Medical Center, Section Editor, Managed Care, is Associate Editor for Infectious Disease Alert.

They all report no financial relationships relevant to this field of study.

Warfarin, the most common vitamin K antagonist in clinical use, consists of two optically active isomers, the R and S enantiomers.1 The S enantiomer primarily undergoes metabolism by the cytochrome P450 (CYP) enzyme 2C9 pathway, and is 3- to 4-fold more potent than the R enantiomer. The CYP1A2 and CYP3A4 pathways are involved in the metabolism of the less potent R enantiomer.1 Warfarin dosing requirements vary greatly among individuals and can be impacted by genetic and environmental factors. Environmental factors include medications, diet, and a variety of disease states, such as liver disease and hypermetabolic conditions.1

Antimicrobials represent a short-term change in patient therapy that can have devastating consequences if certain drug interactions are disregarded or overlooked. The objective of this article is to compile and analyze case reports and other studies showing the interaction between various antimicrobial agents and warfarin. Moreover, this article is intended to heighten clinicians' awareness of the potential interactions between antimicrobial agents and warfarin, such that supratherapeutic or subtherapeutic INRs (international normalized ratios) are prevented and managed.

Overview of Interactions

Table 1 provides a summary of the most commonly implicated antibiotics, with a focus on the probability of the reaction, the proposed mechanism responsible for the interaction, the time of onset/offset (if available) of the interaction, and recommendations for preventing supratherapeutic or subtherapeutic INRs. The probabilities of the interactions were derived from the findings cited in the eighth edition of the American College of Chest Physicians' Clinical Practice Guidelines.

Fifteen antibiotic agents have been shown to interact with warfarin in published case reports over the past four decades. Of note, linezolid, vancomycin, telavancin, daptomycin, quinupristin/dalfopristin, amikacin, gentamicin, neomycin, streptomycin, tobramycin, colistimethate, nitrofurantoin, ethambutol, and pyrazinamide have not been shown to interact with warfarin.

Metronidazole potentiates the effect of warfarin through inhibition of CYP2C9, whereas rifampin induces the metabolism of warfarin through CYP1A2, CYP2C9, and CYP3A4. Ciprofloxacin, erythromycin, clarithromycin, and telithromycin most likely inhibit the metabolism of the R enantiomer of warfarin. Other antibiotics may enhance the anticoagulant effects of warfarin through displacement of warfarin from albumin, or through disruption of intestinal flora responsible for vitamin K synthesis.

Conclusion

In summary, concomitant use of warfarin with metronidazole, trimethoprim/sulfamethoxazole, ciprofloxacin, and erythromycin necessitates dose reduction of warfarin in order to prevent supratherapeutic INRs and/or major bleeding events. In contrast, patients taking warfarin and rifampin concurrently will require more frequent INR monitoring, along with gradual changes in warfarin dosing during the time of dual therapy and up to several months after discontinuation of rifampin therapy. The propensity of other antibiotics to interact with warfarin has not been validated by published case reports, but warrants closer INR monitoring during each treatment course.

References

  1. Ansell J, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133:160-98.
  2. Thompson AH, et al. Intracerebral hemorrhage secondary to a warfarin-metronidazole interaction. Am J Geriatr Pharmacother. 2008;6:33-36.
  3. Tonna AP, et al. Metronidazole causes an unexpected rise in INR in anticoagulated patients even after warfarin has been stopped. Hospital Pharmacist. 2007;14:65-67.
  4. Cook DE, Ponte CD. Suspected trimethoprim/sulfamethoxazole-induced hypoprothrombinemia. J Fam Prac. 1994;39:589-591.
  5. Ellis RJ, Mayo MS, Bodensteiner DM. Ciprofloxacin-warfarin coagulopathy: A case series. Am J Hematol. 2000;63:28-31.
  6. Ahmed A, et al. Impact of preemptive warfarin dose reduction on anticoagulation after initiation of trimethoprim-sulfamethoxazole or levofloxacin. J Thromb Thrombolysis. 2008;26:44-48.
  7. Carroll DN, Carroll DG. Interactions between warfarin and three commonly prescribed fluoroquinolones. Ann Pharmacother. 2008;42:680-685.
  8. Lee CR, Thrasher KA. Difficulties in anticoagulation management during coadministration of warfarin and rifampin. Pharmacotherapy. 2001;21:1240-1246.
  9. Kim KY, et al. Update on the interaction of rifampin and warfarin. Prog Cardiovasc Nurs. 2007;22:97-100.
  10. Krajewski KC. Inability to achieve a therapeutic INR value while on concurrent warfarin and rifampin. J Clin Pharm Online First. published on January 7, 2010 as doi: 10.1177/0091270009353030.
  11. Gooderham MJ, et al. Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin. Ann Pharmacother. 1999;33:796-799.
  12. Interaction of warfarin with macrolide antibiotics. Aust Adv Drug Bull. 1995;14:11.
  13. Parker DL, et al. Elevated international normalized ratio associated with concurrent use of ophthalmic erythromycin and warfarin. Am J Health-Syst Pharm. 2010;67:38-41.
  14. Oberg KC. Delayed elevation of international normalized ratio with concurrent clarithromycin and warfarin therapy. Pharmacotherapy. 1999;18:386-391.
  15. Shrader SP, Fermo JD, Dzikowski AL. Azithromycin and warfarin interaction. Pharmacotherapy. 2004;24:945-949.
  16. Rao KB, et al. Enhanced hypoprothrombinemia with warfarin due to azithromycin. Ann Pharmacother. 2004;38:982-985.
  17. Kolilekas L, et al. Potential interaction between telithromycin and warfarin. Ann Pharmacother. 2004;38:1424-1427.
  18. Halvorsen S, Husebye T, Arnesen H. Prosthetic heart valve thrombosis during dicloxacillin therapy. Scand Cardiovasc J. 1999;33:366-368.
  19. Mailloux AT, Gidal BE, Sorkness CA. Potential interaction between warfarin and dicloxacillin. Ann Pharmacother. 1996;30:1402-1407.
  20. Lacey CS. Interaction of dicloxacillin with warfarin. Ann Pharmacother. 2004;38:898.
  21. Kim KY, et al. Interaction between warfarin and nafcillin: Case report and review of the literature. Pharmacotherapy. 2007;27:1467-1470.
  22. Davydov L, Yermolnik M, Cuni LJ. Warfarin and amoxicillin/clavulanate drug interaction. Ann Pharmacother. 2003;37:367-370.
  23. Angaran DM, et al. The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient: Cefamandole, cefazolin, vancomycin. Ann Surg. 1987;206:155-161.
  24. Baciewicz AM, Bal BS. Bleeding associated with doxycycline and warfarin treatment. Arch Intern Med. 2001;161:1231.